popwess
Member
- Messages
- 6
- Location
- Derbyshire
A new drug for Type 2 diabetes launched in the UK could save the NHS £70 million over the next five years, according to its manufacturer.
Lixisenatide, marketed under the name Lyxumia, is self-administered once a day using an injection pen.
The drug acts on a naturally occurring hormone called GLP-1 to help diabetes sufferers control levels of insulin in their blood.
At £1.90 per daily dose, lixisenatide is said to be less than a quarter of the price of existing similar treatments.
Health economists employed by the drug's maker, Sanofi, maintain it has the potential to save the NHS £70 million over the next five years.
A head-to-head comparison with another GLP-1 diabetes drug showed that accidental episodes of abnormally low blood sugar were reduced by two thirds in patients using lixisenatide.
Good news :clap: :clap:
Lixisenatide, marketed under the name Lyxumia, is self-administered once a day using an injection pen.
The drug acts on a naturally occurring hormone called GLP-1 to help diabetes sufferers control levels of insulin in their blood.
At £1.90 per daily dose, lixisenatide is said to be less than a quarter of the price of existing similar treatments.
Health economists employed by the drug's maker, Sanofi, maintain it has the potential to save the NHS £70 million over the next five years.
A head-to-head comparison with another GLP-1 diabetes drug showed that accidental episodes of abnormally low blood sugar were reduced by two thirds in patients using lixisenatide.
Good news :clap: :clap:
